Skip to main content
MyDeficiencies

Glimepiride

Sulfonylurea

Also sold as Amaryl.

Analyze another medication Medication directory

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

Glimepiride does not have the pharmacokinetic machinery that drives most classical drug-nutrient depletion syndromes. Per its FDA label, it undergoes complete oxidative biotransformation by CYP2C9 to an active hydroxy metabolite (M1) and then to an inactive carboxy metabolite (M2); no parent drug is recovered unchanged in urine or feces. Glimepiride is a CYP2C9 substrate, not a documented inducer or inhibitor of any CYP450 enzyme, so it does not accelerate catabolism of other compounds the way enzyme-inducing anticonvulsants or rifamycins do. No gastric-pH change, chelation, or bile-acid-sequestration mechanism by which glimepiride itself would interfere with nutrient absorption is documented. On prior plausibility alone, a reader should not expect glimepiride to cause broad vitamin or mineral wasting, and none of the classical nutrient claims investigated for this dossier held up under drug-specific scrutiny.

Sulfonylurea (blood glucose lowering drugs, excl. insulins) · ATC A10BB12 · also sold as Amaryl and generics · reviewed 2026-09-20. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Glimepiride in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe
Two or more independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence.
Orange — Moderate
At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit.
Yellow — Low
Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction.
Not graded — disclosed evidence gap
Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: Not gradeable under the rules above because nothing has been measured. Published as a documented gap, never as reassurance that there is no effect.

What the research found

Sodium - dilutional hyponatremia/SIADH risk, bounded to polypharmacy and comorbid risk factors

Orange — Moderate

See study details

Glimepiride carries a labeled, postmarketing-documented risk of hyponatremia and SIADH; this is a retention/dilutional excess risk, not a sodium deficiency, and is bounded to patients with other contributing medications or conditions.

Full detail and limits

What the grade means here: At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit. orange

Limits on what this shows

  • Negative/null findings: No controlled trial identified that quantifies population-level sodium change with glimepiride specifically; the signal is a labeled postmarketing report, not a measured cohort effect, which is itself the boundary stated in the entry title.
  • At-risk subgroups: Elderly patients, those on concurrent hyponatremia-risk medications, and those with renal impairment (which also raises glimepiride metabolite exposure, per the pharmacokinetic basis above).
  • Counter-evidence: None identified suggesting glimepiride raises sodium or protects against hyponatremia; the direction is consistently toward retention/dilution when it occurs.

Regulatory status

FDA labeling for glimepiride tablets lists postmarketing reports of "hyponatremia and syndrome of inappropriate antidiuretic hormone secretion (SIADH), most often in patients on other medications or with conditions that cause hyponatremia or increase release of antidiuretic hormone."

Population evidence

Tier A regulatory label statement (postmarketing spontaneous-report signal); the label itself states the boundary (comorbid/polypharmacy patients), rather than reporting a quantified incidence or effect size in a controlled cohort.

Mechanism

Named: sulfonylurea-class potentiation of antidiuretic hormone release/action, producing dilutional hyponatremia, most plausible in patients who are elderly, volume-depleted, or co-prescribed other hyponatremia-risk drugs (e.g. diuretics, SSRIs, carbamazepine).

Counter-evidence held on record

This is an excess/retention risk, not a dietary sodium deficiency. Do not present this as a reason to increase sodium intake or supplement sodium; the hazard runs the opposite direction, and any sodium correction in a hyponatremic patient must be managed by a clinician because of the risk of overly rapid correction.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial burden - mitochondrial K ATP channel interaction, low affinity relative to older sulfonylureas

Yellow — Low

See study details

Glimepiride's core mechanism (closing ATP-sensitive potassium channels) also acts, off-target from the pancreas, on the mitochondrial/sarcolemmal K ATP channel isoform in cardiac tissue; pharmacology characterizes glimepiride as comparatively low-affinity here versus glyburide/glipizide, but animal data on whether it still blunts ischemic preconditioning are mixed.

Full detail, limits and 1 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. yellow

Limits on what this shows

  • Key negative/null findings: At least one more recent rodent infarct-model study (identified via Europe PMC search, not independently re-opened due to rate-limiting) reported that co-administered glimepiride increased infarct size and blocked cardioprotection in that specific model, conflicting with the 2001 finding of no abolition of protection. This conflict is recorded rather than resolved.
  • At-risk subgroups: Patients undergoing acute ischemic events (e.g. percutaneous coronary intervention) while on a sulfonylurea, where blunted ischemic preconditioning is the theoretical concern; low-affinity agents such as glimepiride are the more commonly recommended choice within the class when this is a concern.
  • Counter-evidence: The 2001 Circulation study and the low-affinity pharmacology classification both point toward glimepiride being comparatively reassuring versus glyburide/glipizide on this specific mechanism; this is itself counter-evidence against treating glimepiride as equivalent to high-affinity sulfonylureas.

Regulatory status

Not addressed in FDA labeling as a mitochondrial effect; labeling describes only the intended pancreatic beta-cell K ATP closure mechanism.

Population evidence

A 2001 canine/pharmacology study in Circulation (DOI 10.1161/01.CIR.103.25.3111), titled "Glimepiride, a Novel Sulfonylurea, Does Not Abolish Myocardial Protection Afforded by Either Ischemic Preconditioning or Diazoxide," reported that, unlike glyburide, glimepiride at clinically relevant concentrations did not block protection from preconditioning or from the mitochondrial K ATP opener diazoxide. Full text could not be independently re-verified in this review (see access note); the finding is reported at title/abstract-indexing confidence. Separately, pharmacology reviews classify glimepiride as "low-affinity" for the mitochondrial K ATP channel compared to high-affinity agents (glyburide, glipizide), with real-world cardiovascular-event data showing lower comparative risk for low-affinity sulfonylureas.

Mechanism

Named: sulfonylurea receptor-mediated closure of the mitochondrial/sarcolemmal K ATP channel (SUR2A/Kir6.2 in cardiac tissue), distinct from the pancreatic SUR1/Kir6.2 target that produces the drug's intended insulin-secretagogue effect. This off-target channel effect, not the intended pancreatic action, is what is graded here.

Counter-evidence held on record

This is a mechanistic, drug-class-comparative signal, not a measured mitochondrial injury or nutrient-style deficiency in glimepiride-treated patients, and it must not be conflated with the drug's intended pancreatic mechanism (Hard Rule 2). Evidence is conflicting between studies and was not independently re-verified for every source due to a tooling access limitation disclosed in the sources list.

Oxidative Stress

Each finding below is counted once, in this area only.

Oxidative stress - reduced

Yellow — Low

See study details

Two small trials adding glimepiride to existing therapy found reduced malondialdehyde and altered superoxide dismutase levels afterward, a plausibly protective rather than depleting signal, but design limitations (active comparator, no untreated arm) keep this below orange.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. yellow

Limits on what this shows

  • Key negative/null findings: Both human studies are active-comparator or combination-vs-monotherapy designs; neither includes an untreated or placebo diabetic comparator, so confounding by improved glycemic control (rather than a direct redox effect of glimepiride) cannot be excluded.
  • At-risk subgroups: Not applicable; the direction found is protective, not a deficit requiring subgroup flagging.
  • Counter-evidence: The active-comparator design in both trials is itself a limitation: it shows glimepiride is not worse than (and on MDA, somewhat better than) another sulfonylurea or than glimepiride monotherapy versus combination, but not that glimepiride improves oxidative status versus no antidiabetic treatment.

Regulatory status

Not addressed in FDA labeling.

Population evidence

Observational comparative study, 66 uncontrolled type 2 diabetic patients on metformin, randomized to add-on glimepiride or gliclazide for 16 weeks (Iraqi Journal of Pharmaceutical Sciences): in the glimepiride arm, superoxide dismutase fell significantly (P=0.026) and malondialdehyde fell significantly (P<0.001); glutathione and protein carbonyl changes were non-significant (P=0.214 and P=0.538). Gliclazide showed a significantly larger improvement in protein carbonyl than glimepiride (P=0.048). Separately, a 189-patient retrospective study (99 glimepiride+sitagliptin, 90 glimepiride monotherapy) found the combination arm had lower MDA and higher SOD/glutathione peroxidase than the monotherapy arm; this compares two active treatments and does not establish glimepiride's own effect versus no treatment.

Mechanism

Not definitively named; proposed explanations include improved glycemic control itself reducing hyperglycemia-driven oxidative stress, rather than a direct antioxidant action of glimepiride. A separate mouse model (MPTP-induced dopaminergic degeneration) reported glimepiride attenuated oxidative stress and glial activation, consistent in direction but in an unrelated (neurologic) context and species.

Counter-evidence held on record

This is a reverse-direction (potentially protective) finding, not a depletion, and must not be marketed as an indication for antioxidant supplementation; supplementation was not tested in any cited study.

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Copper

Not graded — disclosed evidence gap

See study details

Copper

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. ungraded

Limits on what this shows

  • Why no grade: No Tier B or Tier C evidence connecting glimepiride, or sulfonylureas as a class, to copper status was found, and no circulating consumer claim about glimepiride and copper was found to rebut as white. Searches were run across DailyMed, StatPearls, PubMed, and general web search using multiple phrasings ("glimepiride iron copper trace mineral diabetes," combined copper/iron/microbiome queries against Europe PMC). Partway through this review, PubMed abstract pages began returning bot-verification challenges and the Europe PMC REST API and the WebFetch retrieval tool began returning sustained HTTP 429 rate-limit responses that did not clear after repeated waits of up to several minutes, preventing further deep-dive queries specifically for copper. This entry may reflect a true evidence gap, a genuine tooling limitation at the time of writing, or both; a revision should re-run copper-specific queries once access is confirmed clear.

Iron

Not graded — disclosed evidence gap

See study details

Iron

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. ungraded

Limits on what this shows

  • Why no grade: No Tier B or Tier C evidence connecting glimepiride, or sulfonylureas as a class, to iron status (ferritin, transferrin saturation, serum iron) was found, and no circulating consumer claim specifically alleging glimepiride depletes iron was found. This is distinct from the G6PD-hemolysis finding graded above under oxygen delivery/utilization, which concerns red-cell destruction risk in a genetic subgroup, not iron intake, absorption, or storage. Search access degraded (bot-verification pages, sustained 429 responses on PubMed and Europe PMC) before an exhaustive class-level iron search could be completed; disclosed as a possible tooling limitation alongside a possible true gap.

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome risk

Not graded — disclosed evidence gap

See study details

Gut microbiome risk

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. ungraded

Limits on what this shows

  • Why no grade: No drug-specific or class-level (sulfonylurea) evidence of gut microbiome composition or diversity change was found. Antidiabetic-microbiome literature located during this review concentrates on metformin and GLP-1 receptor agonists; sulfonylureas were not identified as a studied class in any microbiome paper reviewed. A consumer source found during the circulating-claim audit attributes "probiotic" depletion specifically to metformin, not to sulfonylureas or glimepiride, so there is no circulating glimepiride-specific claim to rebut as white either. Europe PMC queries combining glimepiride/sulfonylurea with microbiome/microbiota terms were attempted but the API began returning sustained rate-limit errors before results could be confirmed; this is disclosed as a possible tooling limitation.

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

Oxygen delivery/utilization - hemolytic anemia risk bounded to G6PD-deficient patients

Yellow — Low

See study details

A published case report describes glimepiride-induced hemolytic anemia in a patient with glucose-6-phosphate dehydrogenase (G6PD) deficiency; this is a real but case-report-level, genetically bounded risk to red-cell mass and oxygen-carrying capacity.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. yellow

Limits on what this shows

  • Key negative/null findings: The clinical-trial oxidative-stress evidence above (yellow entry, general type 2 diabetic populations) found glimepiride associated with reduced, not increased, oxidative markers; that population was not selected for G6PD status, so it neither confirms nor refutes the G6PD-specific hemolysis signal, but it does show the general-population redox direction is not itself alarming.
  • At-risk subgroups: Patients with G6PD deficiency, a genetic condition more prevalent in individuals of African, Mediterranean, Middle Eastern, and Southeast Asian descent.
  • Counter-evidence: This rests on Tier B case-report evidence only; no cohort or pharmacovigilance-database study specifically quantifying glimepiride-associated hemolysis incidence in G6PD-deficient patients was verified in this review.

Regulatory status

Not confirmed present in the current FDA glimepiride label in the sources opened for this review; StatPearls' glimepiride adverse-effects summary (accessed for this review) does not list G6PD-related hemolysis specifically.

Population evidence

Case report: "Glimepiride-Induced Hemolytic Anemia in a Patient with Glucose-6-Phosphate Dehydrogenase Deficiency: A Side Effect of Sulfonylurea that is Overlooked in Clinical Practice" (single patient). Identified via search; full text was not independently opened for this review, so design and outcome details beyond the title could not be verified.

Mechanism

Plausible: G6PD-deficient red cells have reduced capacity to buffer oxidant stress; sulfonylureas are among the drug classes reported, in case literature, to precipitate hemolysis in this genetic subgroup, analogous to (though generally less potent an oxidant trigger than) drugs like dapsone or primaquine.

Counter-evidence held on record

This is a drug-induced hemolysis risk in a specific genetic subgroup, not a nutrient (e.g. iron or B12) deficiency, and is listed under the oxygen-delivery category rather than filed as an iron-status finding (Hard Rule 2). It is not a reason to supplement iron; G6PD status, not iron intake, is the relevant risk factor.

ATP production

Not graded — disclosed evidence gap

See study details

ATP production

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. ungraded

Limits on what this shows

  • Why no grade: No study measuring cellular ATP synthesis or output specifically (as distinct from the mitochondrial K ATP channel-gating evidence graded separately under mitochondrial burden) was found for glimepiride or sulfonylureas as a class, and no circulating claim specifically alleging glimepiride impairs ATP production was found. Glimepiride's core pharmacology (sensing the cellular ATP/ADP ratio to gate a potassium channel) is the drug's own intended mechanism in pancreatic beta cells and is not, by itself, evidence of impaired ATP synthesis; conflating the two would violate Hard Rule 2. This category was searched with more limited depth than others because it was reached after PubMed and Europe PMC access had already degraded during this session (see access notes); a revision should re-run ATP-production-specific queries once access is confirmed clear.

Claims checked and not supported

These circulate online for this medication. They are listed here only so they can be answered, never as findings, and they are not graded.

A claim with no supporting evidence is not necessarily disproven. Where evidence actually argues against a claim, that is stated below.

  • Coenzyme Q10

    Where it comes from: Consumer "drug mugging" content (e.g. a diabetes-medication nutrient-depletion article) lists sulfonylureas, including glimepiride by name, as CoQ10 depleters, citing "a study on coenzyme Q10 published in 1976."

    Why it fails: Glimepiride was not approved until 1995 and could not have been studied in 1976. PubMed and Europe PMC searches for "coenzyme Q10 sulfonylurea," "coenzyme Q10 glimepiride," and "tolbutamide ubiquinone" returned no human or animal study linking any sulfonylurea (first- or later-generation) to CoQ10 depletion; returned results concerned unrelated topics (sulfonylurea herbicide biodegradation, generic CoQ10 cell biology). No Tier B or Tier C support exists at any level for this drug or its class.

  • Vitamin B12

    Where it comes from: General "diabetes medications" nutrient-depletion lists include vitamin B12; a cross-sectional study title explicitly frames the finding as "Metformin-Induced Vitamin B12 Deficiency" that is more prevalent when metformin is combined with a sulfonylurea versus insulin.

    Why it fails: The cited study is cross-sectional and observational, and its estimates are pooled across the sulfonylureas studied. Its title states a metformin-induced framing, but a title is not a result and cannot establish causation or dismiss what the analysis reports: sulfonylurea use remained an independent risk factor for B12 deficiency on multivariate analysis in metformin-treated patients. That adjusted association is preserved here, not refuted. What is absent is a glimepiride-specific mechanism: metformin's B12 mechanism (calcium-dependent ileal intrinsic-factor-B12 complex absorption) has no documented counterpart in glimepiride's pharmacology (complete hepatic metabolism, no ileal transporter interaction documented), and confounding by more advanced disease or additive glycemic-control needs cannot be excluded in a cross-sectional design. The finding is therefore an unresolved pooled-sulfonylurea association in combination therapy, and is not a glimepiride-specific depletion claim in either direction.

  • Folate (folic acid)

    Where it comes from: The same general "diabetes medications" consumer lists that name B12 also name folic acid, without drug-level distinction.

    Why it fails: No mechanism or drug-specific/class-specific study was found implicating glimepiride or sulfonylureas in folate depletion; the only nutrient-depletion mechanism identified in the literature for diabetes drugs and folate/B12 again traces to metformin specifically.

All references used above
  1. Glimepiride Tablets, USP - full prescribing information — FDA regulatory label. DailyMed, U.S. National Library of Medicine. Used for mechanism, PK, metabolism, elimination, CYP450 interactions, and the hyponatremia/SIADH postmarketing signal.
  2. WHO Collaborating Centre for Drug Statistics Methodology, ATC/DDD Index, code A10BB12 — Regulatory classification reference. Confirms ATC code, class (sulfonylureas), and DDD (2 mg oral).
  3. Glimepiride - StatPearls — NCBI Bookshelf, NBK554600. Pharmacology reference. Used for mechanism detail, adverse-effect list, and confirming no nutrient/mitochondrial/microbiome effects are described in this reference.
  4. Impact of Gliclazide Modified Release or Glimepiride as Add-on Therapy to Metformin on Glycemic and Oxidative Stress Parameters in Type 2 Diabetic Patients — Observational comparative study, 66 patients (33/33), 16 weeks, Thi-Qar specialized diabetic center. Iraqi Journal of Pharmaceutical Sciences. Glimepiride specifically in the cohort. Used for the oxidative-stress yellow entry (SOD P=0.026, MDA P<0.001, GSH P=0.214, protein carbonyl P=0.538, gliclazide superior on protein carbonyl P=0.048).
  5. Influence of glimepiride plus sitagliptin on treatment outcome, blood glucose, and oxidative stress in diabetic patients — Retrospective comparative study, 189 patients (99 glimepiride+sitagliptin, 90 glimepiride monotherapy), 2017-2021. PMC9641479. Glimepiride specifically in both arms; no untreated comparator, so limited to supporting evidence.
  6. Glimepiride, a Novel Sulfonylurea, Does Not Abolish Myocardial Protection Afforded by Either Ischemic Preconditioning or Diazoxide — Circulation, 2001. DOI 10.1161/01.CIR.103.25.3111. Used for the mitochondrial-burden yellow entry, title/abstract-indexing confidence only.Full text could not be opened during this review (403 error); cited at title-level confidence, flagged in the entry.
  7. Europe PMC REST API search: glimepiride AND ischemic preconditioning — Search-API results used for supplementary, lower-confidence characterization of mitochondrial K ATP channel affinity (glimepiride "low-affinity" vs glyburide/glipizide "high-affinity") and a conflicting rodent infarct-model finding, referenced in the mitochondrial-burden entry.Individual constituent records (e.g. PMID 41017568, PMID 35294529) could not be independently re-opened and cross-verified before the Europe PMC API began returning sustained HTTP 429 responses; treated as lower-confidence supplementary evidence only.
  8. Glimepiride-Induced Hemolytic Anemia in a Patient with Glucose-6-Phosphate Dehydrogenase Deficiency: A Side Effect of Sulfonylurea that is Overlooked in Clinical Practice — Case report. Used for the oxygen-delivery/utilization yellow entry.Identified by title via search; full text was not opened in this review, so only the title-stated finding is used, and the entry is explicit about this limitation.
  9. PubMed search listing: "coenzyme q10 sulfonylurea" — Search-listing page reviewed to confirm absence of relevant human/animal studies; all ten results were unrelated (CoQ10 general cell biology, sulfonylurea herbicide biodegradation) rather than antidiabetic-sulfonylurea CoQ10 studies. Used as negative evidence for the CoQ10 fails-verification entry.
  10. Don't get mugged by your diabetes medication — Senior Voice Alaska, 2013. Consumer nutrient-depletion source (Tier D). Origin of the circulating CoQ10 claim for sulfonylureas/glimepiride (citing an unspecified "1976" study) and confirmation that B12/folate/probiotic claims for diabetes drugs in this source are attributed to metformin, not sulfonylureas.
  11. Nutrient depletion is an often overlooked side effect of some medications — Michigan State University College of Pharmacy resource. Consumer/professional education source (Tier D for drug-specific purposes). Lists "Diabetes medications - CoQ10, folic acid, vitamin B-12" as a general, non-drug-stratified entry; glimepiride and sulfonylureas not named specifically.
  12. Higher Prevalence of Metformin-Induced Vitamin B12 Deficiency in Sulfonylurea Combination Compared with Insulin Combination in Patients with Type 2 Diabetes: A Cross-Sectional Study — PLOS One, 2014; PubMed 25299054. Cited in the B12 fails-verification entry as an observational, cross-sectional study of pooled sulfonylurea-plus-metformin therapy reporting an adjusted association. Its title states a metformin-induced framing, which does not itself establish causation.Full text (PLOS One, 403 error) and PubMed abstract page (bot-verification challenge) could not be opened during this review; the study's causal framing is taken from its own title and indexed metadata only, not from a fully read abstract or methods section.